Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

Cationic amphiphilic bolaamphiphile-based delivery of antisense oligonucleotides provides a potentially microbiome sparing treatment for C. difficile.

Sharma AK, Krzeminski J, Weissig V, Hegarty JP, Stewart DB.

J Antibiot (Tokyo). 2018 Aug;71(8):713-721. doi: 10.1038/s41429-018-0056-9. Epub 2018 Apr 19.

2.

A review of orexin's unprecedented potential as a novel, highly-specific treatment for various localized and metastatic cancers.

Graybill NL, Weissig V.

SAGE Open Med. 2017 Nov 3;5:2050312117735774. doi: 10.1177/2050312117735774. eCollection 2017. Review.

3.

PEGylated-nanoliposomal clusterin for amyloidogenic light chain-induced endothelial dysfunction.

Guzman-Villanueva D, Migrino RQ, Truran S, Karamanova N, Franco DA, Burciu C, Senapati S, Nedelkov D, Hari P, Weissig V.

J Liposome Res. 2018 Jun;28(2):97-105. doi: 10.1080/08982104.2016.1274756. Epub 2017 Feb 10.

4.

Liposomes Came First: The Early History of Liposomology.

Weissig V.

Methods Mol Biol. 2017;1522:1-15. Review.

PMID:
27837526
5.

The Eighth Central European Conference "Chemistry towards Biology": Snapshot.

Perczel A, Atanasov AG, Sklenář V, Nováček J, Papoušková V, Kadeřávek P, Žídek L, Kozłowski H, Wątły J, Hecel A, Kołkowska P, Koča J, Svobodová-Vařeková R, Pravda L, Sehnal D, Horský V, Geidl S, Enriz RD, Matějka P, Jeništová A, Dendisová M, Kokaislová A, Weissig V, Olsen M, Coffey A, Ajuebor J, Keary R, Sanz-Gaitero M, van Raaij MJ, McAuliffe O, Waltenberger B, Mocan A, Šmejkal K, Heiss EH, Diederich M, Musioł R, Košmrlj J, Polański J, Jampílek J.

Molecules. 2016 Oct 17;21(10). pii: E1381.

6.

Mitochondria-Targeted Agents: Mitochondriotropics, Mitochondriotoxics, and Mitocans.

Guzman-Villanueva D, Weissig V.

Handb Exp Pharmacol. 2017;240:423-438. doi: 10.1007/164_2016_37. Review.

PMID:
27590226
7.

Bolaamphiphile-based nanocomplex delivery of phosphorothioate gapmer antisense oligonucleotides as a treatment for Clostridium difficile.

Hegarty JP, Krzeminski J, Sharma AK, Guzman-Villanueva D, Weissig V, Stewart DB Sr.

Int J Nanomedicine. 2016 Aug 1;11:3607-19. doi: 10.2147/IJN.S109600. eCollection 2016.

8.

Monosialoganglioside-Containing Nanoliposomes Restore Endothelial Function Impaired by AL Amyloidosis Light Chain Proteins.

Franco DA, Truran S, Weissig V, Guzman-Villanueva D, Karamanova N, Senapati S, Burciu C, Ramirez-Alvarado M, Blancas-Mejia LM, Lindsay S, Hari P, Migrino RQ.

J Am Heart Assoc. 2016 Jun 13;5(6). pii: e003318. doi: 10.1161/JAHA.116.003318.

9.

Nanoliposomes protect against human arteriole endothelial dysfunction induced by β-amyloid peptide.

Truran S, Weissig V, Madine J, Davies HA, Guzman-Villanueva D, Franco DA, Karamanova N, Burciu C, Serrano G, Beach TG, Migrino RQ.

J Cereb Blood Flow Metab. 2016 Feb;36(2):405-12. doi: 10.1177/0271678X15610134. Epub 2015 Oct 8.

10.

Treatment Strategies that Enhance the Efficacy and Selectivity of Mitochondria-Targeted Anticancer Agents.

Modica-Napolitano JS, Weissig V.

Int J Mol Sci. 2015 Jul 29;16(8):17394-421. doi: 10.3390/ijms160817394. Review.

11.

Nanocarrier-based antioxidant therapy: promise or delusion?

Weissig V, Guzman-Villanueva D.

Expert Opin Drug Deliv. 2015;12(11):1783-90. doi: 10.1517/17425247.2015.1063611. Epub 2015 Jun 29. Review.

PMID:
26119920
12.

Erratum.

Weissig V, Edeas M.

Methods Mol Biol. 2015;1265:E1. doi: 10.1007/978-1-4939-2288-8_33. No abstract available.

PMID:
25835967
13.

Mitochondrial medicine. Preface.

Weissig V, Edeas M.

Methods Mol Biol. 2015;1265:v-xiv. No abstract available.

PMID:
25793241
14.

Mitochondrial medicine. Preface.

Weissig V, Edeas M.

Methods Mol Biol. 2015;1264:v-xiv. No abstract available.

PMID:
25789388
15.

Nanopharmaceuticals (part 2): products in the pipeline.

Weissig V, Guzman-Villanueva D.

Int J Nanomedicine. 2015 Feb 11;10:1245-57. doi: 10.2147/IJN.S65526. eCollection 2015. Review.

16.

DQAsomes as the prototype of mitochondria-targeted pharmaceutical nanocarriers: preparation, characterization, and use.

Weissig V.

Methods Mol Biol. 2015;1265:1-11. doi: 10.1007/978-1-4939-2288-8_1.

PMID:
25634263
17.

Nanopharmaceuticals (part 1): products on the market.

Weissig V, Pettinger TK, Murdock N.

Int J Nanomedicine. 2014 Sep 15;9:4357-73. doi: 10.2147/IJN.S46900. eCollection 2014. Review.

18.

Nanoliposomes protect against AL amyloid light chain protein-induced endothelial injury.

Truran S, Weissig V, Ramirez-Alvarado M, Franco DA, Burciu C, Georges J, Murarka S, Okoth WA, Schwab S, Hari P, Migrino RQ.

J Liposome Res. 2014 Mar;24(1):69-73. doi: 10.3109/08982104.2013.838258. Epub 2013 Nov 15.

19.

Targeting mitochondria: strategies, innovations and challenges: The future of medicine will come through mitochondria.

Edeas M, Weissig V.

Mitochondrion. 2013 Sep;13(5):389-90. doi: 10.1016/j.mito.2013.03.009. Epub 2013 Apr 3.

PMID:
23562877
20.

Mitochondria-specific nano-emulsified therapy for myocardial protection against doxorubicin-induced cardiotoxicity.

Faulk A, Weissig V, Elbayoumi T.

Methods Mol Biol. 2013;991:99-112. doi: 10.1007/978-1-62703-336-7_11.

PMID:
23546663
21.

Protective role of clusterin in preserving endothelial function in AL amyloidosis.

Franco DA, Truran S, Burciu C, Gutterman DD, Maltagliati A, Weissig V, Hari P, Migrino RQ.

Atherosclerosis. 2012 Nov;225(1):220-3. doi: 10.1016/j.atherosclerosis.2012.08.028. Epub 2012 Sep 1.

22.

Mitochondria-specific nanocarriers for improving the proapoptotic activity of small molecules.

Weissig V.

Methods Enzymol. 2012;508:131-55. doi: 10.1016/B978-0-12-391860-4.00007-0.

PMID:
22449924
23.

Mitochondrial delivery of biologically active molecules.

Weissig V.

Pharm Res. 2011 Nov;28(11):2633-8. doi: 10.1007/s11095-011-0588-1. Epub 2011 Sep 21. No abstract available.

PMID:
21935741
24.

From serendipity to mitochondria-targeted nanocarriers.

Weissig V.

Pharm Res. 2011 Nov;28(11):2657-68. doi: 10.1007/s11095-011-0556-9. Epub 2011 Aug 11. Review.

PMID:
21833792
25.

Implications of intracellular distribution of nanovesicles for bioimaging studies.

Elbayoumi T, Weissig V.

J Biomed Nanotechnol. 2009 Dec;5(6):620-33. Review.

PMID:
20201224
26.

Liposomes for drug delivery to mitochondria.

Boddapati SV, D'Souza GG, Weissig V.

Methods Mol Biol. 2010;605:295-303. doi: 10.1007/978-1-60327-360-2_20.

PMID:
20072889
27.

Mitochondria-targeted liposomes improve the apoptotic and cytotoxic action of sclareol.

Patel NR, Hatziantoniou S, Georgopoulos A, Demetzos C, Torchilin VP, Weissig V, D'Souza GG.

J Liposome Res. 2010 Sep;20(3):244-9. doi: 10.3109/08982100903347931.

PMID:
19883213
28.

Subcellular targeting: a new frontier for drug-loaded pharmaceutical nanocarriers and the concept of the magic bullet.

D'Souza GG, Weissig V.

Expert Opin Drug Deliv. 2009 Nov;6(11):1135-48. doi: 10.1517/17425240903236101. Review.

PMID:
19708822
29.

Nanocarrier-assisted sub-cellular targeting to the site of mitochondria improves the pro-apoptotic activity of paclitaxel.

D'Souza GG, Cheng SM, Boddapati SV, Horobin RW, Weissig V.

J Drug Target. 2008 Aug;16(7):578-85. doi: 10.1080/10611860802228855.

PMID:
18686127
30.

Organelle-targeted nanocarriers: specific delivery of liposomal ceramide to mitochondria enhances its cytotoxicity in vitro and in vivo.

Boddapati SV, D'Souza GG, Erdogan S, Torchilin VP, Weissig V.

Nano Lett. 2008 Aug;8(8):2559-63. doi: 10.1021/nl801908y. Epub 2008 Jul 9.

PMID:
18611058
31.

Induction of apoptosis and necrosis in human peripheral blood mononuclear cells by fatty acid ethyl esters.

Alhomsi K, Selig M, Sustic T, Katrangi E, Weissig V, Laposata M.

Alcohol Clin Exp Res. 2008 Mar;32(3):534-43. doi: 10.1111/j.1530-0277.2007.00597.x. Epub 2008 Jan 22.

PMID:
18215210
32.

Xenogenic transfer of isolated murine mitochondria into human rho0 cells can improve respiratory function.

Katrangi E, D'Souza G, Boddapati SV, Kulawiec M, Singh KK, Bigger B, Weissig V.

Rejuvenation Res. 2007 Dec;10(4):561-70.

PMID:
18069915
33.

Mitochondria-specific nanotechnology.

Weissig V, Boddapati SV, Jabr L, D'Souza GG.

Nanomedicine (Lond). 2007 Jun;2(3):275-85. Review.

PMID:
17716174
34.

Mitochondriotropics: a review of their mode of action, and their applications for drug and DNA delivery to mammalian mitochondria.

Horobin RW, Trapp S, Weissig V.

J Control Release. 2007 Aug 28;121(3):125-36. Epub 2007 Jun 14. Review.

PMID:
17658192
35.

Gene therapy of the other genome: the challenges of treating mitochondrial DNA defects.

D'Souza GG, Boddapati SV, Weissig V.

Pharm Res. 2007 Feb;24(2):228-38. Epub 2006 Dec 19. Review.

PMID:
17180727
36.

Liposomes and liposome-like vesicles for drug and DNA delivery to mitochondria.

Weissig V, Boddapati SV, Cheng SM, D'Souza GG.

J Liposome Res. 2006;16(3):249-64. Review.

PMID:
16952879
37.

Targeted drug delivery to mammalian mitochondria in living cells.

Weissig V.

Expert Opin Drug Deliv. 2005 Jan;2(1):89-102. Review.

PMID:
16296737
38.

Mitochondriotropic liposomes.

Boddapati SV, Tongcharoensirikul P, Hanson RN, D'Souza GG, Torchilin VP, Weissig V.

J Liposome Res. 2005;15(1-2):49-58.

PMID:
16194927
39.
40.

Mitochondrial pharmaceutics.

Weissig V, Cheng SM, D'Souza GG.

Mitochondrion. 2004 Mar;3(4):229-44.

PMID:
16120357
41.
42.

Approaches to mitochondrial gene therapy.

D'Souza GG, Weissig V.

Curr Gene Ther. 2004 Sep;4(3):317-28. Review.

PMID:
15384945
43.

DQAsome-mediated delivery of plasmid DNA toward mitochondria in living cells.

D'Souza GG, Rammohan R, Cheng SM, Torchilin VP, Weissig V.

J Control Release. 2003 Sep 19;92(1-2):189-97.

PMID:
14499196
44.

In vivo biodistribution of erythrocytes and polyethyleneglycol-phosphatidylethanolamine micelles carrying the antitumour agent dequalinium.

Lizano C, Weissig V, Torchilin VP, Sancho P, García-Pérez AI, Pinilla M.

Eur J Pharm Biopharm. 2003 Sep;56(2):153-7.

PMID:
12957627
45.

Mitochondrial-targeted drug and DNA delivery.

Weissig V.

Crit Rev Ther Drug Carrier Syst. 2003;20(1):1-62. Review.

PMID:
12911263
46.

Antiactin-targeted immunoliposomes ameliorate tissue plasminogen activator-induced hemorrhage after focal embolic stroke.

Asahi M, Rammohan R, Sumii T, Wang X, Pauw RJ, Weissig V, Torchilin VP, Lo EH.

J Cereb Blood Flow Metab. 2003 Aug;23(8):895-9.

PMID:
12902833
47.

Intracellular targets for DNA delivery: nuclei and mitochondria.

Torchilin VP, Khaw BA, Weissig V.

Somat Cell Mol Genet. 2002 Nov;27(1-6):49-64. Review.

PMID:
12774940
48.

DQAsome/DNA complexes release DNA upon contact with isolated mouse liver mitochondria.

Weissig V, D'Souza GG, Torchilin VP.

J Control Release. 2001 Aug 10;75(3):401-8.

PMID:
11489326
49.

Mitochondriotropic cationic vesicles: a strategy towards mitochondrial gene therapy.

Weissig V, Torchilin VP.

Curr Pharm Biotechnol. 2000 Dec;1(4):325-46. Review. Erratum in: Curr Pharm Biotechnol 2001 Jun;2(2):208.

PMID:
11467330
50.

TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors.

Torchilin VP, Rammohan R, Weissig V, Levchenko TS.

Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8786-91. Epub 2001 Jul 3.

Supplemental Content

Loading ...
Support Center